Monoclonal Antibody to Phospholipase A2, Cytosolic (cPLA2)
| Code | Size | Price |
|---|
| MAB624Hu21-20ul | 20ul | £87.00 |
Quantity:
| MAB624Hu21-100ul | 100ul | £162.00 |
Quantity:
| MAB624Hu21-200ul | 200ul | £219.00 |
Quantity:
| MAB624Hu21-1ml | 1ml | £502.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Flow Cytometry
- Immunocytochemistry (ICC)
- Immunofluorescence (IF)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
c-PLA2; cPLA2; PLA2G4A; Phospholipase A2, Cytosolic; Phospholipase A2,Group IV(Cytosolic,Calcium-Dependent); Phosphatidylcholine 2-acylhydrolase; Lysophospholipase
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Cytosolic Phospholipase A2
Potency (Clone Number):
C19
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.5-3ug/mL;<br/>Immunohistochemistry: 5-30ug/mL;<br/>Immunocytochemistry: 5-30ug/mL;<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Phospholipase A2, Cytosolic (cPLA2) | RPB624Hu02 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||